Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free NRSN Stock Alerts

NeuroSense Therapeutics (NRSN) Financials

NeuroSense Therapeutics logo
$0.70 -0.02 (-2.31%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$0.71 +0.01 (+0.81%)
As of 07/16/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for NeuroSense Therapeutics

Annual Income Statements for NeuroSense Therapeutics

This table shows NeuroSense Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.46 -5.72 -9.63 -10 -10 -10 -11
Consolidated Net Income / (Loss)		 -2.46 -5.72 -9.63 -10 -10 -10 -11
Net Income / (Loss) Continuing Operations		 -2.46 -5.72 -9.63 -10 -10 -10 -11
Total Pre-Tax Income 		-2.46 -5.72 -9.63 -10 -10 -10 -11
Total Operating Income		 -2.47 -5.78 -11 -11 -12 -9.90 -11
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.47 5.78 11 11 12 9.90 11
Selling, General & Admin Expense		 0.34 0.39 2.51 4.97 4.78 4.20 4.86
Research & Development Expense		 0.90 2.50 3.08 5.59 7.27 5.70 6.23
Total Other Income / (Expense), net		 0.01 0.06 1.55 0.06 1.94 -0.31 -0.04
Other Income / (Expense), net		 0.01 0.06 2.73 0.06 1.94 -0.31 -0.04
Basic Earnings per Share		 ($0.26) ($0.51) ($0.65) ($0.91) ($0.74) ($0.54) ($0.44)
Weighted Average Basic Shares Outstanding		 - - - 11.50M 13.64M 18.60M 25.48M
Diluted Earnings per Share		 ($0.26) ($0.51) - ($0.91) ($0.74) ($0.54) ($0.44)
Weighted Average Diluted Shares Outstanding		 - - - 11.50M 13.64M 18.60M 25.48M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 11.78M 15.38M 23.23M 32.56M

Quarterly Income Statements for NeuroSense Therapeutics

No quarterly income statements for NeuroSense Therapeutics are available.

Annual Cash Flow Statements for NeuroSense Therapeutics

This table details how cash moves in and out of NeuroSense Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.81 -0.20 10 -7.52 -0.90 0.74 -3.21
Net Cash From Operating Activities		 -0.58 -0.70 -1.54 -7.62 -8.35 -10 -7.67
Net Cash From Continuing Operating Activities		 -0.58 -0.68 -2.14 -7.62 -8.35 -10 -7.60
Net Income / (Loss) Continuing Operations		 -1.22 -2.83 -4.04 -10 -10 -10 -11
Consolidated Net Income / (Loss)		 -1.22 -2.83 -4.04 -10 -10 -10 -11
Depreciation Expense		 0.00 0.00 0.00 0.01 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.61 2.06 1.42 1.84 -0.11 0.91 2.18
Changes in Operating Assets and Liabilities, net		 0.03 0.08 0.48 1.03 1.84 -0.86 1.33
Net Cash From Investing Activities		 -0.03 -0.01 -0.02 -3.59 3.47 0.00 -0.01
Net Cash From Continuing Investing Activities		 -0.01 -0.01 -0.02 -3.59 3.47 0.00 -0.01
Purchase of Property, Plant & Equipment		 -0.01 -0.01 -0.02 -0.07 -0.03 -0.00 -0.01
Other Investing Activities, net		 - - - -3.52 3.50 0.00 0.00
Net Cash From Financing Activities		 1.42 0.51 12 3.77 3.98 11 4.43
Net Cash From Continuing Financing Activities		 1.42 0.51 11 3.77 3.98 11 4.43
Repayment of Debt		 -0.00 0.00 0.00 0.00 -0.36 -0.39 -0.12
Issuance of Common Equity		 1.42 0.51 9.86 0.00 4.33 11 4.53
Other Financing Activities, net		 0.00 0.00 1.24 3.87 0.01 0.00 0.02
Other Net Changes in Cash		 - - - -0.09 0.01 -0.04 0.04
Cash Interest Received		 - 0.00 0.00 0.05 0.18 0.00 0.01

Quarterly Cash Flow Statements for NeuroSense Therapeutics

No quarterly cash flow statements for NeuroSense Therapeutics are available.

Annual Balance Sheets for NeuroSense Therapeutics

This table presents NeuroSense Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.78 11 7.71 3.19 4.58 1.03
Total Current Assets		 0.77 11 3.80 2.92 4.40 0.78
Cash & Equivalents		 0.70 11 3.54 2.64 3.38 0.17
Restricted Cash		 - - - 0.04 0.04 0.05
Accounts Receivable		 0.03 0.31 0.26 0.24 0.99 0.57
Plant, Property, & Equipment, net		 0.01 0.02 0.08 0.09 0.07 0.06
Total Noncurrent Assets		 0.00 0.00 3.84 0.16 0.11 0.19
Long-Term Investments		 - - - - 0.02 0.02
Other Noncurrent Operating Assets		 - 0.00 3.84 0.16 0.08 0.17
Total Liabilities & Shareholders' Equity		 0.78 11 7.71 3.19 4.58 1.03
Total Liabilities		 0.12 2.43 2.09 4.94 1.99 2.59
Total Current Liabilities		 0.12 0.60 1.73 3.46 1.99 2.52
Accounts Payable		 0.12 0.60 1.73 1.46 1.16 0.80
Other Current Liabilities		 - 0.00 - 2.00 0.83 1.72
Total Noncurrent Liabilities		 0.00 1.83 0.37 1.49 0.00 0.07
Other Noncurrent Operating Liabilities		 - - 0.22 1.49 0.00 0.07
Total Equity & Noncontrolling Interests		 0.66 9.01 5.62 -1.76 2.58 -1.56
Total Preferred & Common Equity		 0.66 9.01 5.62 -1.76 2.58 -1.56
Total Common Equity		 -4.41 -8.45 5.62 -1.76 2.58 -1.56
Common Stock		 0.00 0.00 - 24 39 46
Retained Earnings		 -4.41 -8.45 -21 -26 -37 -48

Quarterly Balance Sheets for NeuroSense Therapeutics

No quarterly balance sheets for NeuroSense Therapeutics are available.

Annual Metrics And Ratios for NeuroSense Therapeutics

This table displays calculated financial ratios and metrics derived from NeuroSense Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 11,781,963.00 15,379,042.00 15,379,042.00 15,379,042.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 11,781,963.00 15,379,042.00 15,379,042.00 15,379,042.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 -0.89 -0.66 -0.66 -0.72
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -1.73 -4.04 -7.82 -7.39 -8.43 -6.93 -7.76
Return On Investment Capital (ROIC_SIMPLE)		 - - - -128.13% 479.49% -268.35% 497.40%
Earnings before Interest and Taxes (EBIT)		 -2.46 -5.72 -8.44 -10 -10 -10 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.46 -5.71 -8.44 -10 -10 -10 -11
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.97 -7.63 -9.88 -1.75 -11 -6.82
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -0.08 -0.27 2.22 -4.46 -0.85 -1.80
Increase / (Decrease) in Invested Capital		 0.00 -0.08 -0.19 2.49 -6.68 3.61 -0.94
Book Value per Share		 $0.00 ($2.20) ($4.22) $0.51 ($0.15) $0.17 ($0.06)
Tangible Book Value per Share		 $0.00 ($2.20) ($4.22) $0.51 ($0.15) $0.17 ($0.06)
Total Capital		 0.00 0.66 9.01 5.77 -1.76 2.58 -1.56
Total Debt		 0.00 0.00 0.00 0.15 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.15 0.00 0.00 0.00
Net Debt		 0.00 -0.74 -11 -3.40 -2.68 -3.44 -0.24
Capital Expenditures (CapEx)		 0.01 0.01 0.02 0.07 0.03 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.09 -0.29 -1.47 -3.22 -1.00 -1.95
Debt-free Net Working Capital (DFNWC)		 0.00 0.65 11 2.07 -0.54 2.41 -1.74
Net Working Capital (NWC)		 0.00 0.65 11 2.07 -0.54 2.41 -1.74
Net Nonoperating Expense (NNE)		 0.73 1.67 1.81 3.10 1.67 3.28 3.37
Net Nonoperating Obligations (NNO)		 0.00 -0.74 -9.27 -3.40 -2.70 -3.44 -0.24
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.01 0.02 0.02 0.02
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.65) ($1.07) ($0.83) ($0.54) ($0.44)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 11.78M 15.38M 18.60M 25.48M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.65) ($1.07) $0.00 ($0.54) ($0.44)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 11.78M 15.38M 18.60M 25.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.65) ($1.07) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 11.78M 15.38M 23.23M 32.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.73 -4.04 -7.82 -7.39 -8.43 -6.93 -7.76
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for NeuroSense Therapeutics

No quarterly metrics and ratios for NeuroSense Therapeutics are available.


Financials Breakdown Chart

NeuroSense Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NeuroSense Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

NeuroSense Therapeutics' net income appears to be on an upward trend, with a most recent value of -$11.13 million in 2025, rising from -$2.46 million in 2019. The previous period was -$10.21 million in 2024. Check out NeuroSense Therapeutics' forecast to explore projected trends and price targets.

NeuroSense Therapeutics' total operating income in 2025 was -$11.09 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.09 million

Over the last 6 years, NeuroSense Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

NeuroSense Therapeutics' total liabilities were at $2.59 million at the end of 2025, a 29.9% increase from 2024, and a 2,056.7% increase since 2020.

In the past 5 years, NeuroSense Therapeutics' cash and equivalents has ranged from $166 thousand in 2025 to $11.06 million in 2021, and is currently $166 thousand as of their latest financial filing in 2025.

Over the last 6 years, NeuroSense Therapeutics' book value per share changed from 0.00 in 2019 to -0.06 in 2025, a change of -6.1%.


Related Companies

Financial statements for NASDAQ:NRSN last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel